Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting.
Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. Lung Cancer. 2018 06; 120:62-69.